Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 6 | 2015 | 189 | 0.560 |
Why?
|
| Antirheumatic Agents | 4 | 2015 | 65 | 0.310 |
Why?
|
| Fatigue | 2 | 2007 | 187 | 0.270 |
Why?
|
| Psychometrics | 1 | 2005 | 357 | 0.190 |
Why?
|
| Biological Products | 2 | 2015 | 189 | 0.190 |
Why?
|
| Severity of Illness Index | 1 | 2005 | 2013 | 0.140 |
Why?
|
| Surveys and Questionnaires | 2 | 2007 | 3022 | 0.130 |
Why?
|
| Rheumatology | 1 | 2015 | 47 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2015 | 370 | 0.100 |
Why?
|
| Microcirculation | 1 | 1993 | 101 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 1993 | 419 | 0.090 |
Why?
|
| Monocytes | 1 | 1993 | 219 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 1993 | 440 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2011 | 191 | 0.080 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 80 | 0.080 |
Why?
|
| Autoantibodies | 1 | 2011 | 287 | 0.080 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2011 | 244 | 0.070 |
Why?
|
| Methotrexate | 1 | 2007 | 227 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2007 | 358 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2011 | 1445 | 0.050 |
Why?
|
| Synovitis | 2 | 1995 | 17 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 480 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 985 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 1416 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2005 | 2787 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2007 | 7387 | 0.030 |
Why?
|
| E-Selectin | 2 | 1995 | 31 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 2 | 1995 | 184 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 1995 | 33 | 0.030 |
Why?
|
| Methoxsalen | 1 | 1995 | 15 | 0.030 |
Why?
|
| Ultraviolet Therapy | 1 | 1995 | 17 | 0.030 |
Why?
|
| Arthritis, Psoriatic | 1 | 1995 | 37 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 315 | 0.030 |
Why?
|
| Knee Joint | 1 | 1995 | 177 | 0.020 |
Why?
|
| P-Selectin | 1 | 1993 | 14 | 0.020 |
Why?
|
| L-Selectin | 1 | 1993 | 17 | 0.020 |
Why?
|
| Platelet Membrane Glycoproteins | 1 | 1993 | 18 | 0.020 |
Why?
|
| Humans | 8 | 2015 | 98135 | 0.020 |
Why?
|
| Frozen Sections | 1 | 1993 | 51 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1993 | 290 | 0.020 |
Why?
|
| Risk Factors | 2 | 2015 | 6232 | 0.020 |
Why?
|
| Aged | 3 | 2007 | 21760 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 725 | 0.020 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2011 | 10 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 682 | 0.020 |
Why?
|
| Middle Aged | 4 | 2007 | 29442 | 0.020 |
Why?
|
| Adult | 3 | 2007 | 29564 | 0.020 |
Why?
|
| Alleles | 1 | 2011 | 1159 | 0.020 |
Why?
|
| Male | 4 | 2007 | 47109 | 0.020 |
Why?
|
| Female | 4 | 2007 | 51570 | 0.020 |
Why?
|
| Adalimumab | 1 | 2007 | 94 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2482 | 0.020 |
Why?
|
| DNA | 1 | 2011 | 1274 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2558 | 0.010 |
Why?
|
| United States | 1 | 2015 | 8193 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 1099 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2011 | 3621 | 0.010 |
Why?
|
| Serum Globulins | 1 | 1995 | 12 | 0.010 |
Why?
|
| Blood Sedimentation | 1 | 1995 | 13 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 58 | 0.010 |
Why?
|
| Synovial Membrane | 1 | 1995 | 33 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1995 | 58 | 0.010 |
Why?
|
| Placebos | 1 | 1995 | 209 | 0.010 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1995 | 77 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 9713 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1995 | 214 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1995 | 803 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1995 | 977 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1995 | 1783 | 0.010 |
Why?
|
| Biopsy | 1 | 1995 | 1224 | 0.010 |
Why?
|